AML score that combines genetic and epigenetic changes might help guide therapy

January 7, 2014

(Medical Xpress)—Currently, doctors use chromosome markers and gene mutations to determine the best treatment for a patient with acute myeloid leukemia (AML). But a new study suggests that a score based on seven mutated genes and the epigenetic changes that the researchers discovered were present might help guide treatment by identifying novel subsets of patients.

The findings, published in the Journal of Clinical Oncology, comes from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

The epigenetic change used in the study is DNA methylation. It involves the addition of methyl groups to DNA, which can reduce or silence a gene's activity, or expression. Abnormal DNA methylation alters normal gene expression and often plays an important role in cancer development.

Overall, the findings suggest that patients with a low score – indicating that one or none of the seven genes is overexpressed in AML cells – had the best outcomes, and that patients with high scores – that is, with six or seven genes highly expressed – had the poorest outcomes.

"To date, disease classification and prognostication for AML patients have been based largely on chromosomal and genetic markers," says co-senior investigator Clara D. Bloomfield, MD, Distinguished University Professor, Ohio State University Cancer Scholar and Senior Adviser.

"Epigenetic changes that affect gene expression have not been considered. Here we show that in previously recognized and prognostically important mutated genes can identify novel patient subgroups, which might better help guide therapy," says Bloomfield, who is also the William Greenville Pace III Endowed Chair in Cancer Research at Ohio State.

The seven-gene panel was identified in 134 patients aged 60 and older with cytogenetically normal (CN-AML) who had been treated on Cancer and Leukemia Group B (CALGB)/Alliance clinical trials.

The researchers computed a score based on the number of genes in the panel that were highly expressed in patients' AML cells, and retrospectively tested the score in two groups of (age 60 and up) and two groups of younger patients (age 59 and under).

Patients with a low score – indicating that one or none of the seven genes is overexpressed – had the best outcomes. Patients with high scores – that is, with six or seven genes highly expressed – had the poorest outcomes.

"For this seven-gene panel, the fewer highly expressed genes, the better the outcome," says co-senior author Guido Marcucci, MD, professor of medicine and the associate director for translational research at the OSUCCC – James. "In both younger and older patients, those who had no highly expressed genes, or had one highly expressed gene had the best outcomes."

Most adults with AML are not cured by current therapies. Only about 40 percent of patients younger than age 60 and about 10 percent of patients 60 and older are alive after three years, so new strategies for treating the disease and for matching the right patient with the right treatment are needed, Bloomfield says.

For this study, Bloomfield, Marcucci and their colleagues used next-generation sequencing to analyze regions of methylated DNA associated with prognostically important gene mutations in CN-AML cells from 134 patients aged 60 and older.

The seven genes identified by the researchers were CD34, RHOC, SCRN1, F2RL1, FAM92A1, MIR155HG and VWA8. For each of these genes, lower expression and higher DNA methylation were associated with better outcome. A summary score was developed based on the number of genes in the panel showing high expression. The researchers validated the score in four sets of patients: older and younger patients with primary AML, and older and younger patients with CN-AML (355 patients total).

When Bloomfield, Marcucci and their collaborators applied the unweighted score to the initial training set of 134 older patients, those with one or no highly expressed genes had a 96 percent complete-remission rate, 32 percent three-year disease-free survival rate and 39 percent three-year overall survival.

Patients with six-to-seven highly expressed genes, on the other hand, had a 25 percent complete-remission rate, a 0 percent three-year disease-free survival rate and 4 percent three-year overall survival.

For younger adult , those under age 60, those with one or no highly expressed genes had a 91-100 percent complete-remission rate, a 60-65 percent three-year disease-free survival rate, and a 76-82 percent three-year overall survival. Patients with six-to-seven highly expressed genes, on the other hand, had a 53-71 percent complete-remission rate, a 13-17 percent three-year disease-free survival rate and a 7-24 percent three-year overall survival.

"Overall, our findings suggest that the unweighted-summary score is a better model compared with all other prognostic markers and previously reported profiles," Bloomfield says.

Explore further: Study identifies possible new acute leukemia marker, treatment target

More information: "Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score." Guido Marcucci, Pearlly Yan, Kati Maharry, David Frankhouser, Deedra Nicolet, Klaus H. Metzeler, Jessica Kohlschmidt, Krzysztof Mrózek, Yue-Zhong Wu, Donna Bucci, John P. Curfman, Susan P. Whitman, Ann-Kathrin Eisfeld, Jason H. Mendler, Sebastian Schwind, Heiko Becker, Constance Bär, Andrew J. Carroll, Maria R. Baer, Meir Wetzler, Thomas H. Carter, Bayard L. Powell, Jonathan E. Kolitz, John C. Byrd, Christoph Plass, Ramiro Garzon, Michael A. Caligiuri, Richard M. Stone, Stefano Volinia, Ralf Bundschuh, and Clara D. Bloomfield. Journal of Clinical Oncology. 2013.50.6337; published online on December 30, 2013; DOI: 10.1200/JCO.2013.50.6337

Related Stories

Study identifies possible new acute leukemia marker, treatment target

May 13, 2013
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal ...

Gene mutation signals a high risk of recurrence in some older acute-leukemia patients

December 12, 2011
Older people with acute myeloid leukemia and normal looking chromosomes in their cancer cells have a higher risk of recurrence if they have mutations in a gene called ASXL1, according to a new study by researchers at the ...

A microRNA prognostic marker identified in acute leukemia

May 14, 2012
A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes (CN-AML).

High-dose cytarabine improves outcome in patients with AML in EORTC-GIMEMA AML-12 Trial

December 19, 2013
Results of the EORTC and GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto) AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult ...

Reduced intensity regimen prior to marrow transplant better for older leukemia patients

December 10, 2012
A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) shows that preparing older acute myeloid ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.